FI3978074T3 - Terlipressiini tyypin 1 hepatorenaalisen syndrooman hoitamiseksi - Google Patents
Terlipressiini tyypin 1 hepatorenaalisen syndrooman hoitamiseksi Download PDFInfo
- Publication number
- FI3978074T3 FI3978074T3 FIEP21205752.5T FI21205752T FI3978074T3 FI 3978074 T3 FI3978074 T3 FI 3978074T3 FI 21205752 T FI21205752 T FI 21205752T FI 3978074 T3 FI3978074 T3 FI 3978074T3
- Authority
- FI
- Finland
- Prior art keywords
- terlipressin
- patient
- treatment
- blood
- serum creatinine
- Prior art date
Links
- 108010010056 Terlipressin Proteins 0.000 title claims 9
- BENFXAYNYRLAIU-QSVFAHTRSA-N terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 title claims 9
- 229960003813 terlipressin Drugs 0.000 title claims 9
- 201000011200 hepatorenal syndrome Diseases 0.000 title claims 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 8
- 210000004369 blood Anatomy 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 229940109239 creatinine Drugs 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 238000004820 blood count Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/024—Measuring pulse rate or heart rate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14542—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring blood gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
- A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/4925—Blood measuring blood gas content, e.g. O2, CO2, HCO3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
- G01N2015/016—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N2015/1024—Counting particles by non-optical means
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Analytical Chemistry (AREA)
- Cardiology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Physiology (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Ecology (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Dispersion Chemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462068357P | 2014-10-24 | 2014-10-24 | |
| US201562151384P | 2015-04-22 | 2015-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3978074T3 true FI3978074T3 (fi) | 2024-05-20 |
Family
ID=54478246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP21205752.5T FI3978074T3 (fi) | 2014-10-24 | 2015-10-22 | Terlipressiini tyypin 1 hepatorenaalisen syndrooman hoitamiseksi |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10335452B2 (enExample) |
| EP (3) | EP3981420A1 (enExample) |
| JP (4) | JP6673915B2 (enExample) |
| CN (2) | CN114028536B (enExample) |
| AU (1) | AU2015335855A1 (enExample) |
| CA (1) | CA2965325A1 (enExample) |
| DK (2) | DK3209317T3 (enExample) |
| ES (2) | ES2987577T3 (enExample) |
| FI (1) | FI3978074T3 (enExample) |
| HR (1) | HRP20220225T1 (enExample) |
| HU (1) | HUE058066T2 (enExample) |
| PL (2) | PL3978074T3 (enExample) |
| PT (2) | PT3978074T (enExample) |
| SI (1) | SI3209317T1 (enExample) |
| WO (1) | WO2016065117A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ591810A (en) | 2008-09-17 | 2012-12-21 | Chiasma Inc | Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid |
| US20210290725A1 (en) * | 2014-10-24 | 2021-09-23 | Mallinckrodt Pharmaceuticals Ireland Limited | Method of treating patients with hepatorenal syndrome type 1 |
| US20200046798A1 (en) * | 2014-10-24 | 2020-02-13 | Mallinckrodt Hospital Products IP Limited | Method of treating patients with hepatorenal syndrome type 1 |
| HRP20220225T1 (hr) * | 2014-10-24 | 2022-04-29 | Mallinckrodt Pharmaceuticals Ireland Limited | Terlipresin za liječenje hepatorenalnog sindroma tip 1 |
| IL265761B2 (en) * | 2016-10-21 | 2024-11-01 | Amryt Endo Inc | Oral terlipressin compositions for use in treatment of ascites |
| CN114096267B (zh) | 2019-05-22 | 2025-03-18 | 柏欧韦股份有限公司 | 特利加压素制剂 |
| CN110251469B (zh) * | 2019-07-31 | 2021-11-09 | 南京康舟医药科技有限公司 | 一种醋酸特利加压素制剂及其制备方法 |
| CA3159575A1 (en) * | 2019-10-30 | 2021-05-06 | Mallinckrodt Hospital Products IP Unlimited Company | Method of treating patients with hepatorenal syndrome type 1 and low mean arterial pressure |
| WO2023183339A1 (en) * | 2022-03-22 | 2023-09-28 | Ocelot Bio, Inc. | Selective vasopressin receptor agonist for end-stage liver disease |
| US20240156895A1 (en) * | 2022-10-28 | 2024-05-16 | Mallinckrodt Pharmaceuticals Ireland Limited | Compositions for improving kidney function in patients with hepatorenal syndrome |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1188443A1 (en) | 2000-09-15 | 2002-03-20 | Ferring BV | Improved protocol for paracentesis |
| US7785857B2 (en) * | 2006-08-31 | 2010-08-31 | Saint Louis University | Protein C variant |
| GB0617581D0 (en) * | 2006-09-07 | 2006-10-18 | Ucl Business Plc | Biomarkers for assessing liver function |
| US20080221551A1 (en) * | 2007-03-09 | 2008-09-11 | Flowmedica, Inc. | Acute kidney injury treatment systems and methods |
| WO2009037586A2 (en) | 2007-08-14 | 2009-03-26 | Ferring B.V. | Use of peptidic vasopressin receptor agonists |
| BRPI0922021A2 (pt) * | 2008-11-10 | 2019-09-24 | Astute Medical Inc | método para avaliar a condição renal em um indivíduo, e, uso de um ou mais marcadores de lesão renal |
| CN105132395A (zh) | 2009-03-09 | 2015-12-09 | 生物蛋白有限公司 | Mirac蛋白 |
| JP5749255B2 (ja) | 2009-06-08 | 2015-07-15 | ユーシーエル ビジネス ピーエルシー | Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復 |
| BR112013000744A2 (pt) * | 2010-07-14 | 2020-07-14 | Cumberland Emerging Technologies, Inc | uso de um antagonista de receptor de tromboxana a2 para prevenção ou tratamento de síndrome hepatorrenal,encefalopatia hepática,e doenças associadas |
| JP2012159356A (ja) * | 2011-01-31 | 2012-08-23 | Mochida Pharmaceut Co Ltd | 敗血症診断用組合せマーカー |
| CN103254295A (zh) * | 2013-05-31 | 2013-08-21 | 青岛国大生物制药股份有限公司 | 特利加压素的制备方法 |
| HRP20220225T1 (hr) * | 2014-10-24 | 2022-04-29 | Mallinckrodt Pharmaceuticals Ireland Limited | Terlipresin za liječenje hepatorenalnog sindroma tip 1 |
| JP2017014206A (ja) | 2015-06-30 | 2017-01-19 | ナノアンティバイオティクス，インコーポレイテッド | 腹水の治療 |
-
2015
- 2015-10-22 HR HRP20220225TT patent/HRP20220225T1/hr unknown
- 2015-10-22 EP EP21208813.2A patent/EP3981420A1/en active Pending
- 2015-10-22 PT PT212057525T patent/PT3978074T/pt unknown
- 2015-10-22 FI FIEP21205752.5T patent/FI3978074T3/fi active
- 2015-10-22 ES ES21205752T patent/ES2987577T3/es active Active
- 2015-10-22 EP EP21205752.5A patent/EP3978074B1/en active Active
- 2015-10-22 PL PL21205752.5T patent/PL3978074T3/pl unknown
- 2015-10-22 PL PL15791430T patent/PL3209317T3/pl unknown
- 2015-10-22 HU HUE15791430A patent/HUE058066T2/hu unknown
- 2015-10-22 US US14/920,392 patent/US10335452B2/en active Active
- 2015-10-22 EP EP15791430.0A patent/EP3209317B1/en active Active
- 2015-10-22 DK DK15791430.0T patent/DK3209317T3/da active
- 2015-10-22 DK DK21205752.5T patent/DK3978074T3/da active
- 2015-10-22 SI SI201531790T patent/SI3209317T1/sl unknown
- 2015-10-22 PT PT157914300T patent/PT3209317T/pt unknown
- 2015-10-22 CN CN202111342532.XA patent/CN114028536B/zh active Active
- 2015-10-22 ES ES15791430T patent/ES2904492T3/es active Active
- 2015-10-22 CA CA2965325A patent/CA2965325A1/en not_active Abandoned
- 2015-10-22 CN CN201580062745.3A patent/CN107206049B/zh active Active
- 2015-10-22 WO PCT/US2015/056861 patent/WO2016065117A1/en not_active Ceased
- 2015-10-22 JP JP2017521988A patent/JP6673915B2/ja active Active
- 2015-10-22 AU AU2015335855A patent/AU2015335855A1/en not_active Abandoned
-
2019
- 2019-05-14 US US16/411,944 patent/US20190328831A1/en not_active Abandoned
- 2019-08-28 JP JP2019155678A patent/JP6989571B2/ja active Active
-
2021
- 2021-06-21 JP JP2021102221A patent/JP7346494B2/ja active Active
-
2022
- 2022-09-14 JP JP2022146052A patent/JP2022171795A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| PL3978074T3 (pl) | 2024-08-12 |
| EP3981420A1 (en) | 2022-04-13 |
| JP6989571B2 (ja) | 2022-01-05 |
| HUE058066T2 (hu) | 2022-06-28 |
| JP6673915B2 (ja) | 2020-03-25 |
| CN114028536B (zh) | 2024-07-09 |
| WO2016065117A1 (en) | 2016-04-28 |
| CN107206049B (zh) | 2021-12-07 |
| CN114028536A (zh) | 2022-02-11 |
| AU2015335855A1 (en) | 2017-05-18 |
| PT3978074T (pt) | 2024-05-13 |
| JP2017534618A (ja) | 2017-11-24 |
| EP3209317B1 (en) | 2021-12-08 |
| JP2022171795A (ja) | 2022-11-11 |
| DK3209317T3 (da) | 2022-02-07 |
| ES2987577T3 (es) | 2024-11-15 |
| PL3209317T3 (pl) | 2022-05-23 |
| DK3978074T3 (da) | 2024-05-13 |
| PT3209317T (pt) | 2022-01-19 |
| SI3209317T1 (sl) | 2022-05-31 |
| HRP20220225T1 (hr) | 2022-04-29 |
| CN107206049A (zh) | 2017-09-26 |
| JP2019199485A (ja) | 2019-11-21 |
| JP7346494B2 (ja) | 2023-09-19 |
| EP3209317A1 (en) | 2017-08-30 |
| EP3978074B1 (en) | 2024-03-06 |
| US10335452B2 (en) | 2019-07-02 |
| EP3978074A1 (en) | 2022-04-06 |
| CA2965325A1 (en) | 2016-04-28 |
| US20190328831A1 (en) | 2019-10-31 |
| JP2021155433A (ja) | 2021-10-07 |
| ES2904492T3 (es) | 2022-04-05 |
| US20160113994A1 (en) | 2016-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3978074T3 (fi) | Terlipressiini tyypin 1 hepatorenaalisen syndrooman hoitamiseksi | |
| EA201201284A1 (ru) | Система для обработки крови | |
| EP3372685A3 (en) | Cell lines for virus production and methods of use | |
| MY174894A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation | |
| WO2015118537A3 (en) | Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions | |
| WO2016193929A3 (en) | Injecting and monitoring nervous tissue | |
| EP2759332A4 (en) | WATER TREATMENT MEMBRANE HAVING HIGH CHLORINE RESISTANCE AND HIGH PERMEABILITY, AND METHOD OF MANUFACTURING THEREOF | |
| MX382754B (es) | Terapias combinadas para tratar el cancer. | |
| HK1214752A1 (zh) | 由产甲烷菌引起或与之相关的疾病及病状的诊断、选择及治疗方法 | |
| MX2013012785A (es) | Tratamiento del mieloma multiple. | |
| MX2020011190A (es) | Angiotensina ii sola o en combinacion para usarse en el tratamiento de hipotension. | |
| MX373524B (es) | Solución estabilizada de ácido hipocloroso y uso de la misma. | |
| EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
| EA201390925A1 (ru) | Производные санглиферина и способы их получения | |
| NZ702666A (en) | A method of weight reduction | |
| RU2010141064A (ru) | Способ лечения папилломавирусных инфекций, реализуемый через индукцию интерлейкина - 18 | |
| JOP20210347A1 (ar) | طرق لعلاج فيروس نقص المناعة البشرية | |
| MX2022004157A (es) | Metodo de tratamiento de pacientes con sindrome hepatorrenal tipo 1 y presion arterial media baja. | |
| MX2016011002A (es) | Tratamiento de angioedema hereditario con inhibidor c1. | |
| RU2014148877A (ru) | Способы воздействия на экспрессию гена BRCA1 | |
| EA201491629A1 (ru) | Способы лечения рака с использованием липоплатина | |
| RU2013150333A (ru) | Способ лечения заболеваний, ассоциированных со сниженной продукцией bdnf | |
| RU2014142757A (ru) | Способ воздействия на экспрессию гена TCF | |
| RU2012110137A (ru) | Способ лечения инсулинорезистентности | |
| RU2014142756A (ru) | Способы воздействия на экспрессию гена D4DR |